Bora Pharmaceuticals Co (TPE:6472) Cyclically Adjusted Revenue per Share: NT$61.62 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6472 Bora Pharmaceuticals Co Ltd TPE:6472
82 GF Score
Price NT$401.00
GF Value NT$737.35
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Bora Pharmaceuticals Co Cyclically Adjusted Revenue per Share?

Bora Pharmaceuticals Co TPE:6472 +2.17% 82 Cyclically Adjusted Revenue per Share is NT$61.62 as of Dec. 2025. GuruFocus rates TPE:6472 with a GF Score™ of 82/100 and a GF Value™ of NT$737.35 (Significantly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bora Pharmaceuticals Co's adjusted revenue per share for the three months ended in Dec. 2025 was NT$35.932. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$61.62 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Bora Pharmaceuticals Co's average Cyclically Adjusted Revenue Growth Rate was 30.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-22), Bora Pharmaceuticals Co's current stock price is NT$401.00. Bora Pharmaceuticals Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$61.62. Bora Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is 6.51.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bora Pharmaceuticals Co was 18.51. The lowest was 5.62. And the median was 13.46.


Bora Pharmaceuticals Co  (TPE:6472) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bora Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=401.00/61.62
=6.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bora Pharmaceuticals Co was 18.51. The lowest was 5.62. And the median was 13.46.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bora Pharmaceuticals Co Cyclically Adjusted Revenue per Share Related Terms


Bora Pharmaceuticals Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bora Pharmaceuticals Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bora Pharmaceuticals Co Cyclically Adjusted Revenue per Share Chart

Bora Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 35.46 47.32 61.62

Bora Pharmaceuticals Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.32 51.22 54.21 58.27 61.62

TPE:6472 vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bora Pharmaceuticals Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bora Pharmaceuticals Co's Cyclically Adjusted PS Ratio falls into.


TPE:6472
82GF Score
Bora Pharmaceuticals Co Ltd TPE:6472
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bora Pharmaceuticals Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bora Pharmaceuticals Co's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=35.932/324.0540*324.0540
=35.932

Current CPI (Dec. 2025) = 324.0540.

Bora Pharmaceuticals Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 0.721 238.132 0.981
201606 0.759 241.018 1.020
201609 0.866 241.428 1.162
201612 0.915 241.432 1.228
201703 0.816 243.801 1.085
201706 0.904 244.955 1.196
201709 1.080 246.819 1.418
201712 1.198 246.524 1.575
201803 2.587 249.554 3.359
201806 4.141 251.989 5.325
201809 3.521 252.439 4.520
201812 3.459 251.233 4.462
201903 3.512 254.202 4.477
201906 3.442 256.143 4.355
201909 3.571 256.759 4.507
201912 3.576 256.974 4.509
202003 3.300 258.115 4.143
202006 3.125 257.797 3.928
202009 3.439 260.280 4.282
202012 5.661 260.474 7.043
202103 11.711 264.877 14.327
202106 10.229 271.696 12.200
202109 10.137 274.310 11.975
202112 9.800 278.802 11.391
202203 9.504 287.504 10.712
202206 11.554 296.311 12.636
202209 23.229 296.808 25.361
202212 43.683 296.797 47.695
202303 39.263 301.836 42.153
202306 25.742 305.109 27.340
202309 24.963 307.789 26.282
202312 25.035 306.746 26.448
202403 22.673 312.332 23.524
202406 35.347 314.175 36.458
202409 37.544 315.301 38.586
202412 37.878 315.605 38.892
202503 32.985 319.799 33.424
202506 38.357 322.561 38.535
202509 37.851 324.800 37.764
202512 35.932 324.054 35.932

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$61.62 mean?
Bora Pharmaceuticals Co (TPE:6472) has a Cyclically Adjusted Revenue per Share of NT$61.62 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bora Pharmaceuticals Co and its competitors.
Is Bora Pharmaceuticals Co's Cyclically Adjusted Revenue per Share too high?
Bora Pharmaceuticals Co's current Cyclically Adjusted Revenue per Share is NT$61.62. Overall, Bora Pharmaceuticals Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Bora Pharmaceuticals Co's Cyclically Adjusted Revenue per Share of NT$61.62 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bora Pharmaceuticals Co and its competitors. Bora Pharmaceuticals Co's current Cyclically Adjusted Revenue per Share is NT$61.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$737.35, compared to a current price of NT$401.00 — trading 45.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$61.62. Bora Pharmaceuticals Co's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current Cyclically Adjusted Revenue per Share is NT$61.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?

Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$401.00 is trading 45.6% below its estimated GF Value™ of NT$737.35. GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for TPE:6472:

  • Cyclically Adjusted Revenue per Share: NT$61.62
  • GF Value™: NT$737.35 vs. price of NT$401.00 (45.6% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bora Pharmaceuticals Co Business Description

Other Exchanges BORAY:USA
Address No. 2, Aly. 36, Lane 26, Ruiguang Road, 6th Floor, Neihu District, Taipei, TWN, 114
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
82GF Score

Get the complete analysis for TPE:6472

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$401.00
Price
NT$737.35
GF Value